

Cite this: *Nanoscale Adv.*, 2021, 3, 2516

Biogenic selenium nanoparticles produced by *Lactobacillus casei* ATCC 393 inhibit colon cancer cell growth *in vitro* and *in vivo*

Katerina Spyridopoulou,^a Eleni Tryfonopoulou,^a Georgios Aindelis,^a Petros Ypsilantis,^b Charalampos Sarafidis,^c Orestis Kalogirou^c and Katerina Chlichlia^{*a}

Selenium compounds exhibit excellent anticancer properties but have a narrow therapeutic window. Selenium nanoparticles, however, are less toxic compared to other selenium forms, and their biogenic production leads to improved bioavailability. Herein, we used the probiotic strain *Lactobacillus casei* ATCC 393, previously shown to inhibit colon cancer cell growth, to synthesize biogenic selenium nanoparticles. We examined the anticancer activity of orally administered *L. casei*, *L. casei*-derived selenium nanoparticles and selenium nanoparticle-enriched *L. casei*, and investigated their antitumor potential in the CT26 syngeneic colorectal cancer model in BALB/c mice. Our results indicate that *L. casei*-derived selenium nanoparticles and selenium nanoparticle-enriched *L. casei* exert cancer-specific antiproliferative activity *in vitro*. Moreover, the nanoparticles were found to induce apoptosis and elevate reactive oxygen species levels in cancer cells. It is noteworthy that, when administered orally, selenium nanoparticle-enriched *L. casei* attenuated the growth of colon carcinoma in mice more effectively than the isolated nanoparticles or *L. casei*, suggesting a potential additive effect of the nanoparticles and the probiotic. To the best of our knowledge this is the first comparative study examining the anticancer effects of selenium nanoparticles synthesized by a microorganism, the selenium nanoparticle-enriched microorganism and the sole microorganism.

Received 24th November 2020
Accepted 8th March 2021

DOI: 10.1039/d0na00984a

rsc.li/nanoscale-advances

1 Introduction

Selenium (Se) is a nonmetal chemical element primarily found immobilized in sedimentary rocks and soils that has been recognized as an essential trace element.¹ Immobilized Se becomes bioavailable through either the weathering of the soil or the reduction by microorganisms.² It has become evident that Se dietary supplementation has several beneficial effects on human health.^{3,4} Importantly, Se has been reported as a promising compound in cancer prevention and therapy.⁵ Moreover, its anticancer properties have been demonstrated by clinical trials where the most pronounced effects of Se-supplementation were observed against colorectal, lung, and prostate cancers.⁶ There is a narrow window between the beneficial/therapeutic Se dose and the dose that exerts toxicity,⁷ while the degree and mechanism of its toxicity appear to be strictly dependent on its chemical form.⁸

Selenium nanoparticles (nano-Se), due to their nanoscale size and lower surface-area-to-volume ratio, possess distinct physicochemical characteristics compared to other Se forms. Besides being less toxic,⁹ nano-Se have also better bioavailability compared to both Se salts¹⁰ and commercially available yeast-based Se-supplements.¹¹ Therefore, nano-Se are considered an excellent candidate for the replacement of other forms of Se in clinical practice.^{12–14}

Today the most common approach for the synthesis of nano-Se is chemical reduction.¹⁵ However, chemical synthesis is costly, requires special equipment as well as toxic chemicals. It is noteworthy that, in recent years, there has been a great increase in interest in exploiting biosynthetic routes.¹⁶ In particular, various microorganisms have been reported to synthesize nano-Se through their detoxification mechanisms¹⁷ or redox homeostasis.¹⁸ Among the microorganisms able to resist Se toxicity by biologically converting Se oxyanions to the less toxic Se(0), there are certain bacteria that, in the process of Se-anion reduction, synthesize nanoparticles of elemental Se.¹⁹

Se nanoparticles synthesized by bacteria have unique arrangements of Se atoms that vary greatly among different species. These differences reflect the diversity of the enzymes involved in the reduction of Se-oxyanions in different microorganisms.²⁰ The variety of bacteria-derived nano-Se formulations

^aDepartment of Molecular Biology and Genetics, Democritus University of Thrace, University Campus Dragana, 68100 Alexandroupolis, Greece. E-mail: achlichl@mbg.duth.gr

^bLaboratory of Experimental Surgery and Surgical Research, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece

^cDepartment of Physics, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece



demonstrates the complexity of their physicochemical properties and, eventually, the diversity of their biological effects. As previously stated in Oremland *et al.*,²¹ such variety and specificity are difficult to achieve by the traditional methods of synthesis.

Among the various microorganisms that are able to produce nano-Se are *Desulfovibrio desulfuricans*,¹⁸ *Stenotrophomonas maltophilia*, *Rhodobacter sphaeroides*,²² *Pseudomonas alcaliphila*,²³ *Streptococcus thermophilus*, *Lactobacillus acidophilus*, *Lactobacillus casei*¹⁰ and *Lactobacillus plantarum*,²⁴ the last three being probiotic strains that belong to the genus *Lactobacillus*.

Enrichment with nano-Se of certain probiotic microorganisms that possess antiproliferative properties was recently shown to enhance their anticancer activity *in vivo*. In particular, nano-Se enriched *Lactobacillus plantarum* ATCC 8014 inhibited the growth of 4T1 breast tumors in BALB/c mice²⁴ and nano-Se enriched *Lactobacillus brevis* extended the life span and inhibited metastasis to liver in the same 4T1 breast tumor model.²⁵

During the last few years, considerable attention has been paid to the beneficial properties of probiotics, especially to the different species of the genus *Lactobacillus* which have been shown to exert immunomodulatory, anti-inflammatory and anti-carcinogenic strain-specific activities.^{26–28} Our team has been studying the antiproliferative effects of *L. casei* ATCC 393 against colon cancer. We have reported that the oral administration of *L. casei* ATCC 393 significantly impaired tumor growth and raised immune responses in an experimental *in vivo* colon carcinoma model.^{28,29}

This specific *Lactobacillus* strain was first reported to accumulate Se intracellularly in 1995 by Calomme *et al.*³⁰ Even though the researchers did not identify the nanoparticulate nature of these Se aggregates in *L. casei* ATCC 393, they were the first to propose the application of Se-enriched probiotics in nutritional supplementation studies. Later investigations confirmed the synthesis of Se nanoparticles by various probiotic strains¹⁰ and it was only after 2018 that *L. casei* ATCC 393 was found to be among the nano-Se producing probiotic strains.³¹

Herein, we used the probiotic strain *Lactobacillus casei* ATCC 393 (*L. casei*) to synthesize biogenic nano-Se which we isolated and characterized. Moreover, we comparatively examined the anticancer activity of *L. casei*, *L. casei*-derived nano-Se and nano-Se-enriched *L. casei*, and investigated their efficacy as dietary supplements/nutraceuticals for the suppression of colon cancer cell growth in a syngeneic mouse tumor model. Our results indicate that *L. casei*-derived nano-Se and nano-Se-enriched *L. casei* exert cancer-specific antiproliferative activity against colon cancer cells. It is noteworthy that nano-Se-enriched *L. casei* attenuated the growth of colon carcinoma in mice more effectively than *L. casei*-derived nano-Se or *L. casei*, indicating an additive effect between the nanoparticles and the probiotic.

2 Results and discussion

NaHSeO₃ as a Se source for *Lactobacillus casei*

For the biosynthesis of nano-Se by *L. casei* (LC), bacterial cultures were supplemented with 20 μg ml⁻¹ NaHSeO₃ as a Se source and incubated for 96 h until the color of the culture




Fig. 1 Growth of *L. casei* in the presence of NaHSeO₃. Growth of *L. casei* in (a, b) MRS or (c, d) MRS supplemented with NaHSeO₃. Red color of NaHSeO₃-supplied culture compared to standard culture indicates the presence of red elemental selenium. Optical microscopy images (magnification 100×) of bacteria grown in (b) MRS or (d) MRS supplemented with NaHSeO₃ indicate the presence of intracellular sphere-shaped conglomerates only in NaHSeO₃-supplied culture. (e) CFUs in *L. casei* cultures grown in MRS (LC) or MRS supplemented with NaHSeO₃ (LCSe). Both cultures were grown for 19 h with an inoculum of 10⁷ CFUs per ml. CFUs were determined by agar plate counting and three plates per sample were examined. Results presented are representative of three independent experiments. Asterisk indicates a statistically significant difference (Student's *t*-test, *p* ≤ 0.001).

medium turned red (Fig. 1). Interestingly, the bacteria that had grown in the presence of NaHSeO₃ (LCSe), when observed under an optical microscope, appeared to have intracellular aggregated sphere-shaped conglomerates (Fig. 1(d)). As expected, bacterial growth was inhibited by NaHSeO₃. The exact CFUs per ml of the LC or LCSe cultures were determined by counting the colonies grown on agar plates spread with LC or LCSe bacteria in their late log/early stationary phase of culture and found to be $(1.037 \pm 0.018) \times 10^9$ CFUs per ml for LC and $(0.210 \pm 0.014) \times 10^9$ CFUs per ml for LCSe (Fig. 1(e)).

Inhibition of LC growth by NaHSeO₃ is in agreement with previously reported findings where the growth rate of *L. bulgaricus* was found to be significantly inhibited in the presence of a Se source in the same concentration range as the one used in our experiments.³² Moreover, the observation that NaHSeO₃ delays the *L. casei* growth demonstrates the fact that lactobacilli might synthesize nano-Se in order to convert the toxic forms of Se to which they are being exposed, in a relatively harmless form.³³



Extraction and characterization of Se nanoparticles from *Lactobacillus casei*

The observed intracellular conglomerates were extracted from LCSe bacteria and purified. The visible spectrum of isolated conglomerates revealed a peak at 575–585 nm as shown in Fig. 2(a) which is consistent with previously reported absorption spectra of nano-Se.^{34–36} Various species of the genus *Lactobacillus* were shown to possess the ability to synthesize nano-Se. In particular, both *Lactobacillus acidophilus* and *Lactobacillus helveticus*¹⁰ produced nano-Se when they were exposed to NaHSeO₃. In addition, nano-Se were successfully produced by *L. plantarum*³⁷ and *L. brevis*.²⁵ It is noteworthy that *L. casei* was also found to be able to synthesize nano-Se.¹⁰

SEM analysis revealed that the LCSe-isolated conglomerates have a spherical shape (Fig. 2(d)) and a diameter in the

nanoscale range of approximately 170–550 nm with an average of 360 nm and a median of 380 nm (Fig. 2(b)). Furthermore, the signature peaks of Se were detected in the EDS spectrum (Fig. 2(c)) of the conglomerates; thus, we concluded that the conglomerates are spherical nano-Se (SeNps). Our observation, that the probiotic strain *L. casei* ATCC 393 is able to synthesize nano-Se, has been further confirmed by three recently published papers.^{31,38,39}

Most of the microorganisms that are able to produce nano-Se synthesize nanoparticles of a spherical shape.⁴⁰ Their size varies significantly because it depends on the different experimental parameters employed (microbial strain, Se source, incubation period). The polydispersity (170–550 nm, Fig. 2(b)) of the size distribution of the SeNps produced in this work is in good agreement with the literature where the size range of biogenic




Fig. 2 Characterization of extracted SeNps. (a) UV-Vis analysis of SeNps extracted and purified from lysed *L. casei* bacteria cultured in the presence of NaHSeO₃, and dispersed in de-ionized water. Note the peak at 575–585 nm. (b) Size distribution of SeNps analyzed by ImageJ analysis of SEM images. SeNps have a diameter of approximately 170–550 nm with an average of 360 nm and a median of 379 nm. (c) Energy dispersive spectroscopy analysis of the SEM images revealing emission peaks of Se and (d) SEM images of purified SeNps. (e) X-ray diffraction pattern of SeNps.



nano-Se varies between 50 and 500 nm. The average diameter lies at the upper end of the reported distribution range as we observed a Se nanoparticulate formulation of a medium size of 360 nm, while the most common size reported in the literature is ≈ 100 nm.^{16,23,38,41}

We also characterized the isolated nanoparticles by X-ray diffraction (XRD). Their XRD pattern showed a broad peak at 2θ angles of $15\text{--}350^\circ$ (Fig. 2(e)) which suggests that the nanoparticles are amorphous and not crystalline.¹⁶ The amorphous nature of SeNPs is also suggested by their red color. Indeed, biogenic reduction of Se oxyanions induces the formation of amorphous spherical nanoparticles.^{16,21}

Conclusively, by following the method described, from 10^{10} CFUs of LCSe bacteria a nanoparticle yield of $1500\ \mu\text{g}$ of spherical, red amorphous SeNPs with a mean diameter of 360 nm was achieved.

Comparative analysis of the *in vitro* antiproliferative and proapoptotic activity of SeNPs, LCSe and LC

LCSe-isolated SeNPs inhibited CT26 and HT29 colon cancer cell growth of murine or human origin, respectively, in a time- and concentration-dependent manner, while a similar effect was observed for LCSe and LC (Fig. 3(a)). The smaller EC_{50} values against CT26 for 24 or 48 hours estimated for all the treatment groups indicate that CT26 cells are more susceptible to the

antiproliferative effects induced by SeNPs, LCSe or LC than HT29 cells under these experimental settings. Specifically, the EC_{50} values for LCSe after 24 h or 48 h were 7.53 or 7.38 CFUs per ml for CT26 cells, compared to 8.00 or 7.74 for LC respectively and 8.47 or 7.51 for SeNPs (Fig. 3(b)). For HT29 cells, the EC_{50} values for LCSe after 24 h or 48 h were 7.74 or 7.65 CFUs per ml compared to 8.05 or 7.68 for LC respectively and 8.57 or 7.51 for SeNPs (Fig. 3(c)). Both these cell lines are suitable models for the *in vitro* investigation of the antiproliferative properties of bioactive compounds against colon cancer and are commonly used together in such preclinical studies. These cells, being of different origin, have different genetic and epigenetic alterations and different mutations.^{42–44} Therefore, the differences in the EC_{50} values between CT26 and HT29 cells may reflect their phenotypic and functional variability.

Nano-Se have been reported to exhibit antiproliferative effects against various cancer cell lines such as the human Hep-G2 (ref. 45) and H22 (ref. 46) hepatocarcinoma cell lines, the A375 human melanoma cell line,⁴⁷ the HeLa human cervical carcinoma cells and the MDA-MB-231 (ref. 48 and 49) and MCF7 (ref. 49) human breast cancer cell lines. Furthermore, biogenic nano-Se derived from *L. casei* ATCC 393 were previously shown to inhibit the proliferation of the human liver tumor cell line Hep-G2.^{38,50}




Fig. 3 Growth inhibition of CT26 or HT29 cells by SeNPs, *L. casei*-SeNPs or *L. casei*. (a) Cell growth inhibition was analyzed by the SRB assay after 24 or 48 h of treatment. Percentages% of growth inhibition compared to control cells are expressed as mean \pm SD. from six replicates. Estimated EC_{50} values for 24 h or 48 h of treatment in CT26 (b) or HT29 (c) cells. *L. casei*-SeNPs (LCSe) refer to *L. casei* cultured in the presence of NaHSeO_3 ; SeNPs refer to the purified SeNPs from the *L. casei*-SeNPs culture; LC refers to *L. casei*. SeNp concentration refers to the LCSe CFUs, from which the SeNPs were extracted. Data presented are representative of at least four independent experiments.



Regarding *in vitro* colon cancer models, nano-Se have been shown to inhibit the proliferation of Caco-2,^{49,51} HCT-8,⁴⁶ HCT-116 (ref. 49) and Colo-201 (ref. 52) colon cancer cells. It is noteworthy that HT29, the human colon cancer cell line studied in this work, has been previously reported to be sensitive to nano-Se.^{53,54}

Subsequently, focusing on HT29 colon cancer cells of human origin, we observed that part of the antiproliferative effects exerted by SeNPs, LCSe or LC can be attributed to the induction of apoptotic cell death. For the comparative analysis of the apoptotic effects induced by SeNPs, LCSe and LC, the time-dependent dynamic process of apoptosis for each treatment group was studied in a pre-defined time frame (20–26 h) for 10⁸ CFUs per ml for LC and LCSe or 15 μg ml⁻¹ for SeNPs (15 μg of SeNPs were extracted from 10⁸ CFUs of LCSe) by flow cytometric analysis of the double AnnexinV-FITC/PI (AnnexinV-fluorescein isothiocyanate/propidium iodide) staining.

During this time period, all treatments induced apoptosis in HT29 cells, as evident by the early apoptotic cell fraction (AnV + PI-) that moves towards the dead cell fraction (AnV + PI+) (Fig. 4(a)). LC-treated cells move rapidly from the live (AnV-PI-) respectively. As expected, control cells do not present significant alterations in their distribution to the different AnV/PI fractions. The flow cytometry results illustrated in Fig. 4(a) were confirmed with fluorescence microscopy imaging of LC-, LCSe- or SeNp-treated cells under the same conditions for 20 h (Fig. 4(b)).

Probiotics are known to induce and regulate apoptosis in cancer cells by various mechanisms;⁵⁵ the pro-apoptotic activity of *Lactobacillus casei* ATCC 393 has been previously reported by our team.²⁹ Regarding SeNPs, it has been suggested that the main mechanism behind the direct anticancer activity of nano-Se is apoptosis.⁵³ Kong *et al.*⁵⁶ showed that nano-Se induce caspase-mediated apoptosis in prostate LNCaP cancer cells; Zhang *et al.*⁵⁷ showed that nano-Se induce apoptotic cell death in Hep-G2 hepatocarcinoma cells and Yang *et al.*⁵⁸ reported the pro-apoptotic effects of nano-Se against the A375 human melanoma cancer cell line. In all the above-mentioned studies nano-Se were synthesized *via* chemical routes.

Even though there are several studies on the pro-apoptotic effects of chemically synthesized nano-Se or biogenic nano-Se that have been coupled with various therapeutic/targeting compounds,^{57,59,60} there is a paucity of literature on the pro-apoptotic effects of naked biogenic SeNPs. As of today and to the best of our knowledge the pro-apoptotic activity of naked but chemically synthesized SeNPs has been reported in MCF-7 (ref. 61) and A375 (ref. 47) cells *in vitro* and in a hepatocellular carcinoma model in rats *in vivo*.⁶²

SeNPs modulate the protein levels of apoptosis-related molecules and elevate ROS levels in HT29 cells

In order to explore the potential molecular mechanisms of SeNp-induced apoptosis in HT29 cells, the levels of certain apoptosis-related proteins were analyzed in cell lysates. Our results show that various apoptotic signaling proteins were modulated in SeNp-treated HT29 cells (Fig. 4(c)).

The intrinsic apoptosis pathway is inhibited by a group of proteins with structural similarities called IAPs (Inhibitors of Apoptosis Proteins). In humans, there are 6 such proteins, three of which were downregulated by SeNPs. Namely as shown in Fig. 4(d), Survivin was downregulated to 0.8-fold and cIAP1 to 0.6-fold. XIAP, the most well studied protein among IAPs, was upregulated by SeNPs to 3.8-fold (Fig. 4(e)). Interestingly, besides its caspase-inhibitory and anti-apoptotic role, XIAP is also critically involved in the cellular response to oxidative stress by modulating ROS levels.⁶³

The TRAIL death receptors DR4 and DR5 were also upregulated, both at 1.5-fold as illustrated in Fig. 4(e). These receptors bind TRAIL, a type II and potent apoptosis-inducing trans-membrane protein with cancer cell specific action. Interestingly, HT29 cells are TRAIL-resistant,⁶⁴ so SeNPs might induce sensitization of TRAIL-induced apoptosis by upregulating TRAIL death receptors DR4 and DR5.

Two more proteins with anti-oxidant activity were upregulated by SeNPs, both exhibiting a 3-fold rise: PON2 and Catalase (Fig. 4(e)). PON2 is a membrane bound protein that prevents ROS formation. It is noteworthy that overexpression of PON2 has been recently described to inhibit cancer development in a mouse model.⁶⁵ Catalase, an enzyme that protects the cell from oxidative damage,⁶⁶ has been reported to prevent experimental tumor metastasis of colon cancer cells to the lungs and liver.⁶⁷ HIF-1a, a subunit of the heterodimeric transcription factor HIF-1 that plays an important role in hypoxia, was downregulated (0.5-fold) by SeNPs (Fig. 4(d)). HIF-1a, subunit of the heterodimeric transcription factor HIF-1 that plays an important role in hypoxia and has been a target for the development of anticancer drugs that aim to reverse hypoxic resistance to apoptosis in cancer cells,⁶⁸ was downregulated (0.5-fold) by SeNp (Fig. 4(d)).

Cytochrome c is one of the central molecules in apoptotic pathways. In response to apoptotic stimuli, it is being released from the mitochondria to the cytosol where it is involved in the activation of caspases.⁶⁹ In HT29 cells, cytochrome c was downregulated to 0.34-fold by SeNPs (Fig. 4(d)). Interestingly, it has been reported that depletion of cytochrome c sensitizes colon cancer cells to a non-apoptotic and non-autophagic death that can be induced by various stimuli. Moreover, it has been shown that downregulation of cytochrome c in HT29 cells sensitizes them in various anticancer compounds. Lastly, it has been described that cytochrome c depletion enhanced the immunogenicity of colon carcinoma cells in a mouse tumor model.⁷⁰

It is noteworthy that nano-Se have been reported to possess both pro-oxidant⁷¹ as well as anti-oxidant properties.⁹ Moreover, it is well documented in the literature that nano-Se, regardless of the method of their synthesis, induce apoptosis by depletion of mitochondrial membrane potential, cytochrome c release and production of ROS.⁵³ Indeed, SeNPs were found to induce the formation of ROS in HT29 cells in a concentration dependent manner as evident by the DCFDA (carboxy-H₂DCFDA: 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate) flow cytometry histograms in Fig. 5. Our results add to the growing evidence that SeNPs induce apoptosis while the observed






Fig. 4 Detection of apoptosis induced in HT29 cells. (a) Cells were treated with *L. casei* (LC), *L. casei*-SeNps (LCSe) or SeNps for 20–26 h. Cells were stained with Annexin V-FITC and PI, and analyzed by flow cytometry. (b) Fluorescence microscopy images of apoptotic/necrotic cells treated with LC, LCSe or SeNps for 20 h. Cells were stained with Hoechst (blue), Annexin V-FITC (green) and PI (red) and observed under a fluorescence microscope. (c) Expression of apoptosis-related proteins in HT29 cells after SeNp treatment; images of dot plots of protein levels analyzed with a human apoptosis array (ARY009, R&D Systems). Indicated duplicate dots represent a protein expressed in either control or SeNp-treated cells (20 h). Fold change compared to control in the expression levels of selected proteins exhibiting (d) down- or (e) up-regulation upon treatment with SeNps. Dashed lines indicate the expression level in control cells. Cells in all experiments were treated with 10^8 CFUs per ml of either LC or LCSe, or $15 \mu\text{g ml}^{-1}$ of SeNps. The SeNp quantity of $15 \mu\text{g}$ corresponds to the amount of the nanoparticles extracted from 10^8 CFUs of LCSe.



modulation of the expression levels of various proteins involved in redox regulation and in the intrinsic apoptotic path, and the elevated intracellular ROS levels strengthen the hypothesis that a central mechanism of the SeNp-induced apoptosis might be the induction of ROS generation.

SeNps are not toxic to primary murine healthy colonic epithelial cells

Primary cells were isolated from the colon epithelium of healthy BALB/c mice, cultured and treated with 10^8 CFUs per ml of LC or LCSe and $15 \mu\text{g ml}^{-1}$ of SeNps for 24 h ($15 \mu\text{g}$ of SeNps were extracted from 10^8 CFUs of LCSe). Contrary to cancer cells, primary healthy cells were not sensitive to SeNps as shown in Fig. 6(a). CT26 cancer cell growth was inhibited by SeNps to 60% compared to control untreated cells, while SeNp-treated primary cells exhibited a similar to control cell growth rate. Moreover, while LCSe inhibited the growth rate of primary cells to 78%, when CT26 cancer cells were exposed to it, their proliferation rate dropped to 25%. On the contrary, under these experimental settings and for the concentrations used LC seemed to exert similar antiproliferative activity against both cancer and primary healthy cells. Thus, contrary to cancer cells, SeNps are harmless and not toxic to primary healthy cells isolated from the colon of BALB/c mice which is in good agreement with the literature where biogenic nano-Se have been reported

not to affect the viability of human peripheral blood mononuclear cells isolated from healthy volunteers.⁷² Moreover there have been previous reports indicating the cancer specificity of the toxic effects exerted by Se compounds.⁷³

These results indicate that both SeNps and LCSe could possess enhanced cancer-specific antiproliferative properties. Considering the narrow therapeutic window of Se,⁷⁴ this observation is extremely important since it indicates that SeNps could facilitate the therapeutic effects of Se, minimizing its side effects by allowing increased dosage schemes.

Orally administered SeNps inhibit *in vivo* growth of colon carcinoma

Prophylactic oral administration of SeNps (6.5 mg SeNps per kg of total animal weight or $\approx 150 \mu\text{g}$ per mice) in mice for 10 days, as it is described in Fig. 6(b), was well tolerated. Monitoring of mouse weight throughout the experiment did not reveal any significant change between SeNp-treated and Control groups of mice. Moreover, spleen and liver weights were not significantly different between groups (liver index was $6.12\% \pm 0.29$ in Control and $5.6\% \pm 0.32$ in SeNp-treated mice, while the spleen index was $0.98\% \pm 0.15$ in Control and $1.02\% \pm 0.11$ in SeNp-treated mice) (Fig. 6(c) and (d)). Thus, no indication of toxicity was noted, suggesting that the daily administered dose of SeNps is well tolerated. This is in good agreement with Shakibaie




Fig. 5 ROS levels in SeNp-treated HT29 cells. Intracellular levels of ROS were analyzed by flow cytometry using DCFDA. Cells were treated with SeNps (30 or 40 $\mu\text{g ml}^{-1}$) or 200 μM H_2O_2 (positive controls) for 24 h. Only live cells (PI negative) were analyzed. (a) Representative flow graphs showing the gating strategy. (b) Representative fluorescence intensity histograms of cells stained with DCFDA from three independent experiments. MFI stands for Median Fluorescence Intensity. Data were analyzed with FlowJo v.10.






Fig. 6 Biogenic SeNPs attenuate tumor growth in mice. (a) Growth inhibitory effects in murine cancer CT26 or healthy primary colon cells. Primary cells were isolated from the colon of healthy BALB/c mice. Comparative examination with the SRB assay of the antiproliferative activity of *L. casei* (LC), *L. casei*-SeNPs (LCSe) and SeNPs against either CT26 murine colon cancer cells or primary epithelial colon cells. Cells were treated with 10^8 CFUs per ml of LC or LCSe, or $15 \mu\text{g ml}^{-1}$ of SeNPs for 24 h. The quantity of $15 \mu\text{g}$ of SeNPs corresponds to the amount of nanoparticles extracted from 10^8 CFUs of LCSe. Black asterisks indicate a statistically significant difference compared to control and red asterisks a significant difference between cancer and primary healthy cells. (b) Oral administration of SeNPs in mice. Administration scheme. Ten male BALB/c mice were assigned to two groups ($n = 5$). The SeNps group received daily $150 \mu\text{g}$ per mouse of SeNPs for 10 days, while the Control group received PBS. On the seventh day mice were inoculated with CT26 cells and seven days later they were euthanized. Comparison of mean (c) spleen and (d) liver index between SeNp-treated and Control mice. No significant difference was observed between groups. (e) Photographic observation of tumors excised from SeNp-treated and Control mice and (f) mean volume of the excised tumors. A statistically significant $\sim 50\%$ volume inhibition was observed in tumors excised from SeNp-treated mice. (g) Comparative analysis of the effect of SeNPs, LC, and LCSe on tumor growth in mice. Twenty four male BALB/c mice ($n = 6$) received orally in a prophylactic scheme 10^9 CFUs of LC or LCSe or $150 \mu\text{g}$ of SeNps per mouse, once per day, for twelve days. Control mice received PBS. On the tenth day mice were inoculated with 5×10^6 CT26 cells subcutaneously. Mice were euthanized seven days later. (h) Mean volume and (i) photographic observation of tumors excised from SeNps, LC or LCSe-treated and Control mice. A statistically significant reduction in tumor volume was observed in all treatment groups. Statistically significant differences are indicated with asterisks ($*p < 0.05$, Student's *t*-test or one-way ANOVA).



*et al.*⁷⁵ who studied the toxicity of biogenic, spherical and amorphous nano-Se produced by *Bacillus* sp. MSh-1. Specifically, the LD₅₀ value of orally administered nano-Se in mice was determined to be 198.1 mg kg⁻¹, which corresponds to a 30-fold higher dose than the one used in our experiments. Moreover, in the same study it was described that daily oral administration of a dose of up to 10 mg kg⁻¹ of biogenic nano-Se was harmless without side effects in mice. Similar to Shakibaie *et al.*,⁷⁵ our observations substantiate the well-tolerated nature of biogenic SeNps.

It is noteworthy that the oral administration of SeNps according to the schedule described above (Fig. 6(b)) significantly inhibited CT26 tumor growth in BALB/c mice. Specifically, tumors excised from mice that received SeNps were 50% smaller ($p = 0.041$, Student's *t*-test) compared to control animals (Fig. 6(e) and (f)).

Thus, under the above-mentioned experimental settings the orally administered biogenic SeNps produced by LC are well tolerated in mice and induce tumor growth inhibition.

Oral administration of LCSe inhibits the growth of colon carcinoma in mice more effectively than SeNps or LC

Next, we comparatively examined *in vivo* the effect induced by oral administration of SeNps with LCSe or LC in tumor-bearing BALB/c mice, as described in Fig. 6(g). All treatments (SeNps, LCSe, and LC) induced a statistically significant inhibition in tumor growth (Fig. 6(h) and (i)), but LCSe, in accordance with our *in vitro* results illustrated in Fig. (3), exhibited the most potent growth-inhibitory activity. Specifically, LCSe inhibited tumor volume by 77% compared to control, while SeNps induced a reduction of -48% and LC of -54% (Fig. 6(h)).

Regarding LC, our results are in good agreement with previous studies describing the growth inhibitory effects of *L. casei* against colon cancer *in vivo*.^{28,29,76,77} Regarding Se-enriched probiotics like LCSe, there is evidence that they can inhibit tumor growth *in vivo* in pre-clinical studies. In particular, Se-enriched *Lactobacillus plantarum* ATCC 8014 was shown to inhibit the growth of 4T1 breast tumors in BALB/c mice²⁴ and Se-enriched *Bifidobacterium longum* successfully suppressed the proliferation of H22 liver tumor cells in Kunming mice.⁷⁸ Despite the promising results, as of today there are no comparative studies examining the antitumor activity of Se-enriched probiotics. Thus, our observations are extremely important since these findings suggest that the reported growth inhibitory and even pro-apoptotic effects of probiotics may be enhanced *via* their enrichment with nano-Se.

3 Experimental

Materials, animals and cell lines

Materials. Dulbecco's Modified Eagle's Medium (DMEM) and Fungizone (Amphotericin B) were purchased from Gibco (Gaithersburg, MD, USA). Fetal bovine serum (FBS), trypsin, penicillin/streptomycin, and phosphate-buffered saline (PBS) were purchased from Biosera (Boussens, France). MRS Broth, LAB094 and Agar No. 2 (MC006) were purchased from LabM

(UK). The Annexin V-PI kit was purchased from BD Biosciences (USA). The Human Apoptosis Antibody Array kit (ARY 009) from R&D systems (USA) was used. Carboxy-H₂DCFDA (C400) was purchased from Invitrogen (Invitrogen, USA). Acetic acid, trichloroacetic acid (TCA), Trizma base, NaHSeO₃, H₂O₂ and sulforhodamine B (SRB) were purchased from Sigma-Aldrich (Germany).

Mammalian cell lines. The colon carcinoma CT26 (murine) and HT29 (human) cell lines were used. CT26 cells are well characterized and consist one of the most commonly used cell lines in drug development.⁴² HT29 cells are commonly used as an *in vitro* model for the study of new therapeutic interventions against colon cancer. Both cell lines were cultured under sterile conditions at 37 °C in a humidified incubator with 5% CO₂, in DMEM supplemented with 10% fetal bovine serum, penicillin (100 U mL⁻¹) and streptomycin (100 µg mL⁻¹), and 2 mM glutamine.

Primary intestinal (colon) epithelial cells. Primary intestinal epithelial cells were isolated from the colon of three male BALB/c mice (in three individual experiments) as it was previously described.⁷⁹ The protocol described in Chopra *et al.* for the rat colon was adapted for the mouse colon. For culturing, 10⁶ isolated cells were seeded in a 60 mm cell culture dish in 3 ml of DMEM supplemented with 15% fetal bovine serum, penicillin (100 units per ml), streptomycin (100 µg mL⁻¹), and Fungizone (2.5 µg mL⁻¹).

Bacteria. The *Lactobacillus casei* ATCC 393 strain was used for the synthesis of SeNps. *L. casei* ATCC 393 (LC) was grown in MRS broth in 10 ml glass test tubes without agitation at 37 °C. For subculturing 10⁸ CFUs of LC were inoculated in 10 ml MRS. The cultures reached their late-log/early stationary phase (10⁹ CFUs per ml) 19 h post the inoculation. Bacteria were harvested from late-log/early stationary phase cultures by centrifugation at 1700g for 15 minutes at 4 °C. After being washed with PBS, bacteria were resuspended in either DMEM (for the *in vitro* experiments) or PBS (for the *in vivo* experiments) at the indicated CFUs per ml. For the preparation of Se-enriched LC, MRS broth was supplied with 20–60 µg mL⁻¹ NaHSeO₃ inoculated with 10⁷ CFUs per ml of LC, and bacteria were grown for 96 h until reaching the late-log/early stationary phase (LCSe).

Animals. Forty-three male BALB/c mice (6–8 weeks old, weight 20–25 g) were raised in the Animal house unit (Laboratory of Experimental Surgery and Surgical Research at Democritus University of Thrace). Mice were kept in polycarbonate cages and provided with tap water *ad libitum* and a commercial pelleted diet (Mucedola). Animal experiments were approved by the Animal Care and Use Committee of the Veterinary Department of Evros Prefecture since it complied with the requirements set by Directive 86/609/EEC and PD 160/91. All animal experiments were conducted in accordance with the 3 R's (replacement, refinement, and reduction).

Methods

Colony forming units. For the determination of colony-forming units (CFUs) in the bacterial cultures, aliquots of a late log/early stationary LC or LCSe culture were used for seeding the agar plates. For the preparation of the MRS Agar,



the LAB094 MRS Broth and LAB MC006 Agar No. 2 were used. 100 μl of samples were seeded per 100 mm-petri plate filled with 10 ml of MRS Agar. Plates were incubated at 37 °C for 70 h in an anaerobic incubator. CFUs were manually counted on the plates seeded with the 100 000-fold dilution of the initial culture.

Extraction of SeNPs from *Lactobacillus casei*. The method for the isolation of SeNPs from bacteria is an adaptation from the protocol proposed in Kurek *et al.*⁸⁰ First, LCSe bacteria were harvested from the MRS broth by centrifugation (1700 \times g, 15 min, 4 °C). Following three washes with PBS, bacteria were resuspended in NaOH 0.1 M (5 ml of NaOH was used per 0.1 g of bacteria) and incubated at 37 °C for 90 min. The mixture of lysed bacteria and SeNp-clusters was recovered by five subsequent washes with de-ionized water (7000 \times g, 15 min, 4 °C). Harvested clusters containing SeNPs were sonicated (20 rounds of a 5 seconds sonication period, 70% amplitude, 50 W) using the UP50H sonifier from Hielscher Ultrasonics GmbH (Teltow, Germany). Lastly, the dispersed SeNPs were purified from cell debris by vacuum filtration using membrane filters with the pore size ranging from 2 to 0.45 μm . The purified aqueous solution of SeNPs was stored at 4 °C.

UV-Vis spectroscopy of SeNPs. We analyzed the absorption spectrum of the purified SeNPs using the Enspire multi-plate reader (Perkin Elmer). Briefly, 100 μl of SeNPs suspended in deionized water were seeded in a 96-well-plate. Readings were normalized to blank wells containing deionized water.

Scanning electron microscopy and energy dispersion spectroscopy. Scanning electron microscopy (SEM) and Energy Dispersion Spectroscopy (EDS) of extracted SeNPs were carried out using a JEOL JSM-6390LV scanning microscope equipped with an energy-dispersive X-ray (EDS) INCA micro-analytical system. Operating conditions were: accelerating voltage 20 kV, probe current 45 nA and counting time 60 s, with ZAF correction being provided on-line. The samples were coated with carbon, using a Jeol JEE-4X vacuum evaporator. Size distribution of the nanoparticles was determined by ImageJ analysis of multiple SEM images. Results presented are representative of three independent experiments.

Characterization of SeNPs by X-ray crystallography. The structural characterization of SeNPs was carried out using XRD diffractograms with Cu-K α radiation ($\lambda = 1.5405 \text{ \AA}$) in a Bragg-Brentano geometry and analyzed with the Rietveld method.

Cell viability assay. Cell viability was determined by the SRB assay.⁸¹ CT26 or HT29 or primary murine colon epithelial cells were seeded in 96-well plates at a cell density of 5000 cells per well for CT26 or 20 000 for HT29 or primary cells. After treatment, the cells were fixed using ice-cold 10% TCA for 1 h at 4 °C, washed with tap water and dried before being stained with SRB (0.057% w/v) for 30 minutes at room temperature. The excess dye was removed with 1% acetic acid and the cells were dried. Finally, the protein-bound dye was dissolved in 10 mM Tris base and OD (optical density) was measured at 492 nm using the Enspire multi-plate reader (Perkin Elmer). Background levels of OD due to the presence of LC, LCSe or SeNPs were excluded. The % inhibition of cell growth was calculated by eqn (1):

$$\% \text{ growth inhibition} = 100 - [(\text{mean OD sample})/(\text{mean OD control}) \times 100] \quad (1)$$

For the estimation of EC₅₀ values, regression analysis *via* the four-parameter logistic curve was performed using the Sigma plot software v.11.

Light microscopy. For the observation of the bacteria under a light microscope, a Zeiss PrimoVert Inverted Microscope equipped with a ZEISS Axiocam ERC 5C camera was used.

Analysis of apoptosis with the Annexin V-PI assay. Apoptosis was assayed using the Annexin V-PI double staining assay. A commercially available kit (BD Biosciences) was used according to the instructions. HT29 cells were seeded in 10 cm² cell culture plates at a density of 2 \times 10⁶ cells per plate. Upon reaching 70–80% confluency, the cells were treated with LC, LCSe or SeNPs as indicated. Non-treated cells were used as control. Following treatment, the cells were collected by trypsinization and resuspended in Annexin binding buffer. The cells were labeled by 15 minutes-incubation in the dark at room temperature, with Annexin V-FITC and PI and then analysed by flow cytometry (Attune NxT, Thermo Fisher Scientific). Data analysis was performed with FlowJo V10 software.

Intracellular ROS levels. ROS levels were detected by flow cytometry using carboxy-H₂DCFDA. Briefly, 3 \times 10⁶ HT29 cells per well were seeded in 6-well-plates and left to adhere overnight. The cells were treated with SeNPs (30 or 40 $\mu\text{g ml}^{-1}$) or 200 $\mu\text{M H}_2\text{O}_2$ (positive control) for 24 h. Control untreated cells were also included in the experiment. After treatment, the cells were collected with trypsinization and incubated in 18 $\mu\text{M DCFDA}$ in PBS at 37 °C for 40 minutes. The cells were washed and additionally labeled with 2.5 $\mu\text{g ml}^{-1}$ PI for the discrimination of dead cells right before being analyzed with the flow cytometer (Attune NxT, Thermo Fisher Scientific). The cells were excluded based on the PI signal (only PI-negative, thus live cells were analyzed). Data were analyzed with FlowJo v.10.

Oral administration of SeNPs in the CT26 mouse tumor model. Twenty male mice were assigned to two groups ($n = 10$), SeNPs and Control. ‘Control’ animals received daily 150 μl of PBS *per os* while animals in the ‘SeNPs’ group received 150 μg of SeNPs suspended in 150 μl of PBS. The SeNPs dose of 150 μg corresponds to the amount of the nanoparticles extracted from 10⁹ CFUs of LCSe. Oral administration was performed using a gavage needle. On the seventh day, all mice were inoculated with 5 \times 10⁶ CT26 cells subcutaneously in the scuff of the neck, while the oral administration of SeNPs or PBS was continued for the following 3 days. Seven days post CT26 inoculation, mice were euthanized by cervical dislocation and tumors were excised. Tumor dimensions were measured using an electronic micrometer and tumor volume was calculated using the modified ellipsoid formula (eqn (2))

$$[(\text{width}^2 \times \text{length})/2] \quad (2)$$

During the course of the experiments the weight change of each mouse was recorded and all mice were monitored for signs of disease or discomfort. The spleen and liver were also



harvested and weighed. The respective liver and spleen% indexes were calculated with the following formula (eqn (3)):

$$[(\text{spleen/liver weight})/\text{body weight}] \times 100\% \quad (3)$$

Oral administration of SeNps, *L. casei*-SeNps and *L. casei* in the CT26 mouse tumor model. For the comparative evaluation of the *in vivo* growth inhibitory effects of SeNps, LC or LCSe employing the CT26 tumor model, a previously described experimental protocol was followed.^{28,29,82–84} Briefly, 24 male mice were randomly assigned to 4 groups. Mice in each group received a daily dose of 10⁹ CFUs of either LC or LCSe, or 150 µg of SeNps. The nanoparticles or the bacteria were suspended in 150 µl of PBS and were administered *via* a gavage needle for 12 days. The SeNps dose of 150 µg corresponds to the amount of the nanoparticles extracted from 10⁹ CFUs of LCSe. At day ten, 5 × 10⁶ CT26 cells per mouse were injected subcutaneously and the protocol described in the previous paragraph was followed.

Data analysis and statistics. All data are representative of at least three independent experiments and the values are presented as mean ± SD. All data were analyzed with Sigma Plot v. 11.0. Statistical comparisons between groups were performed using the Student's *t*-test or one-way ANOVA where appropriate. Differences between groups were considered statistically significant when $p < 0.05$ ($*p < 0.05$, $**p < 0.01$, $***p < 0.001$).

4 Conclusions

This study provides evidence that SeNps produced by *L. casei* and SeNp-enriched *L. casei* could be good candidates for the development of oral formulations or dietary supplements for the chemoprevention of colon cancer. The evidence presented here indicates that SeNp-enriched probiotic bacteria exert the most potent growth inhibitory effect *in vitro* and *in vivo* as compared to either the isolated SeNps or the sole probiotic, and underlines the importance of comparatively evaluating the biological effects of nanoparticle-enriched probiotics. Moreover, our study adds to the growing evidence that SeNps induce apoptosis in colon cancer cells, possible by inducing ROS generation, among other mechanisms. Along with their strong anticancer potential, the isolated SeNps were also demonstrated to have biocompatibility and cancer-specific growth inhibitory action. However, the anti-proliferative and pro-apoptotic effects exerted by the SeNps and the SeNp-enriched bacteria need to be further characterized and the molecular pathways involved need to be identified. Besides colon cancer, the antiproliferative effects of the SeNps should be investigated against other tumor types in different administration schemes.

While our findings cannot be generalized for various types of cancer or different lactobacilli species, they have revealed the strong potential of nanoparticle-enriched probiotics for cancer prevention while highlighting the importance of comparative assessment and exploitation of their bioactivities. We suggest that future studies on biogenic nanoparticles utilize comparative experimental settings with the aim of figuring out the

complex interactions between bacteria and bacteria-derived nanoparticles that add up to their highly unique bioactivities.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors would like to thank Assoc. Prof. Dr Yannis Kourkoutas (Laboratory of Applied Microbiology & Biotechnology, Dept. of Molecular Biology and Genetics, DUTH) for the *Lactobacillus casei* ATCC 393 strain and Prof. Dr Eleni Pavlidou (Electron Microscopy and Structural Characterization of Materials Laboratory, Dept. of Solid State Physics, AUTH) for her help in the SEM and EDS analysis of the nanoparticles. Part of the work was implemented by utilizing the facilities of the project “An Open-Access Research Infrastructure of Chemical Biology and Target-Based Screening Technologies for Human and Animal Health, Agriculture and the Environment (OPEN-SCREEN-GR)” (MIS 5002691) which is implemented under the Action “Reinforcement of the Research and Innovation Infrastructure”, funded by the Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014–2020) and co-financed by Greece and the European Union (European Regional Development Fund). Part of this study was co-financed by Greece and the European Union (European Social Fund-ESF) through the Operational Programme ‘Human Resources Development, Education and Lifelong Learning 2014–2020’ in the context of the project ‘Biosynthesis of SeNp in probiotic lactobacilli and investigation of their anticancer and immunostimulatory activity’ (MIS 5050556).

References

- 1 K. Schwarz and C. M. Foltz, *J. Am. Chem. Soc.*, 1957, **79**, 3292–3293.
- 2 B. Sarkar, S. Bhattacharjee, A. Daware, P. Tribedi, K. K. Krishnani and P. S. Minhas, *Nanoscale Res. Lett.*, 2015, **10**, 371.
- 3 M. P. Rayman, *Lancet*, 2000, **356**, 233–241.
- 4 B. Hosnedlova, M. Kepinska, S. Skalickova, C. Fernandez, B. Ruttkay-Nedecky, T. D. Malevu, J. Sochor, M. Baron, M. Melcova, J. Zidkova and R. Kizek, *Int. J. Mol. Sci.*, 2017, **18**, 2209.
- 5 C. Sanmartín, D. Plano, A. K. Sharma and J. A. Palop, *Int. J. Mol. Sci.*, 2012, **13**, 9649–9672.
- 6 M. Björnstedt and A. P. Fernandes, *EPMA J.*, 2010, **1**, 389–395.
- 7 J. K. Wrobel, R. Power and M. Toborek, *IUBMB Life*, 2016, **68**, 97–105.
- 8 K. L. Nuttall, *Ann. Clin. Lab. Sci.*, 2006, **36**, 409–420.
- 9 A. Khurana, S. Tekula, M. A. Saifi, P. Venkatesh and C. Godugu, *Biomed. Pharmacother.*, 2019, **111**, 802–812.
- 10 P. Eszenyi, A. Sztrik, B. Babka and J. Prokisch, *Int. J. Biosci., Biochem. Bioinf.*, 2011, **1**, 148–152.
- 11 B. Hosnedlova, M. Kepinska, S. Skalickova, C. Fernandez, B. Ruttkay-Nedecky, Q. Peng, M. Baron, M. Melcova,



- R. Opatrilova, J. Zidkova, G. Bjørklund, J. Sochor and R. Kizek, *Int. J. Nanomed.*, 2018, **13**, 2107–2128.
- 12 S. Skalickova, V. Milosavljevic, K. Cihalova, P. Horiky, L. Richtera and V. Adam, *Nutrition*, 2017, **33**, 83–90.
- 13 J. Zhang, X. Wang and T. Xu, *Toxicol. Sci.*, 2008, **101**, 22–31.
- 14 M. H. Yazdi, M. Masoudifar, B. Varastehmoradi, E. Mohammadi, E. Kheradmand, S. Homayouni and A. R. Shahverdi, *Avicenna J. Med. Biotechnol.*, 2013, **5**, 158–167.
- 15 S. Shoeibi, P. Mozdziaik and A. Golkar-Narenji, *Top. Curr. Chem.*, 2017, **375**, 88.
- 16 A. Husen and K. S. Siddiqi, *J. Nanobiotechnol.*, 2014, **12**, 28.
- 17 N. T. Prakash, N. Sharma, R. Prakash, K. K. Raina, J. Fellowes, C. I. Pearce, J. R. Lloyd and R. A. D. Patrick, *Biotechnol. Lett.*, 2009, **31**, 1857–1862.
- 18 J. Kessi, M. Ramuz, E. Wehrli, M. Spycher and R. Bachofen, *Appl. Environ. Microbiol.*, 1999, **65**, 4734–4740.
- 19 J. F. Stolz, P. Basu, J. M. Santini and R. S. Oremland, *Annu. Rev. Microbiol.*, 2006, **60**, 107–130.
- 20 A. V. Tugarova and A. A. Kamnev, *Talanta*, 2017, **174**, 539–547.
- 21 R. S. Oremland, M. J. Herbel, J. S. Blum, S. Langley, T. J. Beveridge, P. M. Ajayan, T. Sutto, A. V. Ellis and S. Curran, *Appl. Environ. Microbiol.*, 2004, **70**, 52–60.
- 22 A. Yamada, M. Miyashita, K. Inoue and T. Matsunaga, *Appl. Microbiol. Biotechnol.*, 1997, **48**, 367–372.
- 23 W. Zhang, Z. Chen, H. Liu, L. Zhang, P. Gao and D. Li, *Colloids Surf., B*, 2011, **88**, 196–201.
- 24 M. H. Yazdi, M. Mahdavi, E. Kheradmand and A. R. Shahverdi, *Arzneimittelforschung*, 2012, **62**, 525–531.
- 25 M. H. Yazdi, M. Mahdavi, N. Setayesh, M. Esfandyar and A. R. Shahverdi, *Daru, J. Pharm. Sci.*, 2013, **21**, 33.
- 26 A. de M. de LeBlanc and J. G. LeBlanc, *World J. Gastroenterol.*, 2014, **20**, 16518.
- 27 M. L. Marco, S. Pavan and M. Kleerebezem, *Curr. Opin. Biotechnol.*, 2006, **17**, 204–210.
- 28 G. Aindelis, A. Tiptiri-Kourpeti, E. Lampri, K. Spyridopoulou, E. Lamprianidou, I. Kotsianidis, P. Ypsilantis, A. Pappa and K. Chlichlia, *Cancers*, 2020, **12**, 1–16.
- 29 A. Tiptiri-Kourpeti, K. Spyridopoulou, V. Santarmaki, G. Aindelis, E. Tompoulidou, E. E. Lamprianidou, G. Saxami, P. Ypsilantis, E. S. Lampri, C. Simopoulos, I. Kotsianidis, A. Galanis, Y. Kourkoutas, D. Dimitrellou and K. Chlichlia, *PLoS One*, 2016, **11**, e0147960.
- 30 M. Calomme, J. Hu, K. Van den Branden and D. a Vanden Berghe, *Biol. Trace Elem. Res.*, 1995, **47**, 379–383.
- 31 C. Xu, L. Qiao, Y. Guo, L. Ma and Y. Cheng, *Carbohydr. Polym.*, 2018, **195**, 576–585.
- 32 M. Palomo-Siguero, A. M. Gutiérrez, C. Pérez-Conde and Y. Madrid, *Microchem. J.*, 2016, **126**, 488–495.
- 33 G. F. Combs, C. Garbisu, B. C. Yee, A. Yee, D. E. Carlson, N. R. Smith, A. C. Magyarosy, T. Leighton and B. B. Buchanan, *Biol. Trace Elem. Res.*, 1996, **52**, 209–225.
- 34 B. Yu, P. You, M. Song, Y. Zhou, F. Yu and W. Zheng, *New J. Chem.*, 2016, **40**, 1118–1123.
- 35 Q. Li, T. Chen, F. Yang, J. Liu and W. Zheng, *Mater. Lett.*, 2010, **64**, 614–617.
- 36 A. Khalid, P. A. Tran, R. Norello, D. A. Simpson, A. J. O'Connor and S. Tomljenovic-Hanic, *Nanoscale*, 2016, **8**, 3376–3385.
- 37 M. H. Yazdi, M. Mahdavi, B. Varastehmoradi, M. A. Faramarzi and A. R. Shahverdi, *Biol. Trace Elem. Res.*, 2012, **149**, 22–28.
- 38 C. Xu, Y. Guo, L. Qiao, L. Ma, Y. Cheng and A. Roman, *Front. Microbiol.*, 2018, **9**, 1129.
- 39 L. Qiao, X. Dou, S. Yan, B. Zhang and C. Xu, *Food Funct.*, 2020, **11**, 3020–3031.
- 40 R. Jain, N. Jordan, S. Weiss, H. Foerstendorf, K. Heim, R. Kacker, R. Hübner, H. Kramer, E. D. van Hullebusch, F. Farges and P. N. L. Lens, *Environ. Sci. Technol.*, 2015, **49**, 1713–1720.
- 41 S. Dhanjal and S. S. Cameotra, *Microb. Cell Fact.*, 2010, **9**, 1–11.
- 42 J. C. Castle, M. Loewer, S. Boegel, J. de Graaf, C. Bender, A. D. Tadmor, V. Boisguerin, T. Bukur, P. Sorn, C. Paret, M. Diken, S. Kreiter, Ö. Türeci and U. Sahin, *BMC Genomics*, 2014, **15**, 190.
- 43 Y. Liu and W. F. Bodmer, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 976–981.
- 44 D. L. Trainer, T. Kline, F. L. McCabe, L. F. Faucette, J. Feild, M. Chaikin, M. Anzano, D. Reiman, S. Hoffstein, D. -J Li, D. Gennaro, C. Buscarino, M. Lynch, G. Poste and R. Greig, *Int. J. Cancer*, 1988, **41**, 287–296.
- 45 H. Estevez, J. C. Garcia-Lidon, J. L. Luque-Garcia and C. Camara, *Colloids Surf., B*, 2014, **122**, 184–193.
- 46 F. Gao, Q. Yuan, L. Gao, P. Cai, H. Zhu, R. Liu, Y. Wang, Y. Wei, G. Huang, J. Liang and X. Gao, *Biomaterials*, 2014, **35**, 8854–8866.
- 47 T. Chen, Y. S. Wong, W. Zheng, Y. Bai and L. Huang, *Colloids Surf., B*, 2008, **67**, 26–31.
- 48 H. Luo, F. Wang, Y. Bai, T. Chen and W. Zheng, *Colloids Surf., B*, 2012, **94**, 304–308.
- 49 A. A. Abd-Rabou, A. B. Shalby and H. H. Ahmed, *Biol. Trace Elem. Res.*, 2019, **187**, 80–91.
- 50 C. Xu, L. Qiao, Y. Guo, L. Ma and Y. Cheng, *Carbohydr. Polym.*, 2018, **195**, 576–585.
- 51 T. H. D. Nguyen, B. Vardhanabhuti, M. Lin and A. Mustapha, *Food Control*, 2017, **77**, 17–24.
- 52 W. Liu, X. Li, Y. S. Wong, W. Zheng, Y. Zhang, W. Cao and T. Chen, *ACS Nano*, 2012, **6**, 6578–6591.
- 53 M. H. Yazdi, Z. Sepehrizadeh, M. Mahdavi, A. R. Shahverdi and M. A. Faramarzi, *Nano Biomed. Eng.*, 2016, **8**, 246–267.
- 54 V. R. Ranjitha and V. R. Ravishankar, *Pharm. Nanotechnol.*, 2018, **6**, 61–68.
- 55 L. Zhong, X. Zhang and M. Covasa, *World J. Gastroenterol.*, 2014, **20**, 7878.
- 56 L. Kong, Q. Yuan, H. Zhu, Y. Li, Q. Guo, Q. Wang, X. Bi and X. Gao, *Biomaterials*, 2011, **32**, 6515–6522.
- 57 Y. Zhang, X. Li, Z. Huang, W. Zheng, C. Fan and T. Chen, *Nanomedicine*, 2013, **9**, 74–84.
- 58 F. Yang, Q. Tang, X. Zhong, Y. Bai, T. Chen, Y. Zhang, Y. Li and W. Zheng, *Int. J. Nanomed.*, 2012, **7**, 835–844.
- 59 H. Wu, H. Zhu, X. Li, Z. Liu, W. Zheng, T. Chen, B. Yu and K.-H. Wong, *J. Agric. Food Chem.*, 2013, **61**, 9859–9866.



- 60 J. Pi, H. Jin, R. Liu, B. Song, Q. Wu, L. Liu, J. Jiang, F. Yang, H. Cai and J. Cai, *Appl. Microbiol. Biotechnol.*, 2013, **97**, 1051–1062.
- 61 J. Pi, F. Yang, H. Jin, X. Huang, R. Liu, P. Yang and J. Cai, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 6296–6303.
- 62 H. H. Ahmed, W. K. B. Khalil and A. H. Hamza, *Toxicol. Mech. Methods*, 2014, **24**, 593–602.
- 63 U. Resch, Y. M. Schichl, S. Sattler and R. de Martin, *Biochem. Biophys. Res. Commun.*, 2008, **375**, 156–161.
- 64 L. Chen, Y. Meng, X. Guo, X. Sheng, G. Tai, F. Zhang, H. Cheng and Y. Zhou, *Apoptosis*, 2016, **21**, 1291–1301.
- 65 A. Devarajan, F. Su, V. Grijalva, M. Yalamanchi, A. Yalamanchi, F. Gao, H. Trost, J. Nwokedi, G. Farias-Eisner, R. Farias-Eisner, A. M. Fogelman and S. T. Reddy, *Cell Death Discovery*, 2018, **9**, 392.
- 66 C. Glorieux and P. B. Calderon, *Biol. Chem.*, 2017, **398**, 1095–1108.
- 67 A. De Moreno De LeBlanc, J. G. LeBlanc, G. Perdigon, A. Miyoshi, P. Langella, V. Azevedo and F. Sesma, *J. Med. Microbiol.*, 2008, **57**, 100–105.
- 68 T. H. Kim, E. G. Hur, S. J. Kang, J. A. Kim, D. Thapa, Y. Mie Lee, S. K. Ku, Y. Jung and M. K. Kwak, *Cancer Res.*, 2011, **71**, 2260–2275.
- 69 L. Ravagnan, T. Roumier and G. Kroemer, *J. Cell. Physiol.*, 2002, **192**, 131–137.
- 70 E. Schmitt, A. Parcellier, F. Ghiringhelli, N. Casares, S. Gurbuxani, N. Droin, A. Hamai, M. Pequignot, A. Hammann, M. Moutet, A. Fromentin, G. Kroemer, E. Solary and C. Garrido, *Cancer Res.*, 2004, **64**, 2705–2711.
- 71 C. A. Ferreira, D. Ni, Z. T. Rosenkrans and W. Cai, *Nano Res.*, 2018, **11**, 4955–4984.
- 72 P. Sonkusre, *J. Nanomed. Nanotechnol.*, 2014, **05**, 194.
- 73 V. Gandin, P. Khalkar, J. Braude and A. P. Fernandes, *Free Radical Biol. Med.*, 2018, **127**, 80–97.
- 74 A. P. Shreenath, M. A. Ameer and J. Dooley, *Selenium Deficiency*, StatPearls Publishing, 2020.
- 75 M. Shakibaie, A. R. Shahverdi, M. A. Faramarzi, G. R. Hassanzadeh, H. R. Rahimi and O. Sabzevari, *Pharm. Biol.*, 2013, **51**, 58–63.
- 76 K. Yamazaki, *Oncol. Rep.*, 2000, **7**, 977–982.
- 77 S. S. Y. So, M. L. Y. Wan and H. El-Nezami, *Curr. Opin. Oncol.*, 2017, **29**, 62–72.
- 78 J. Yu and J. Zha, *Exp. Ther. Med.*, 2010, **1**, 603–610.
- 79 D. P. Chopra, K. Yeh and R. W. Brockman, *Cancer Res.*, 1981, **41**, 168–175.
- 80 E. Kurek, A. Rusczyńska, M. Wojciechowski, A. Łuciuk, M. Michalska-Kacymirow, I. Motyl and E. Bulska, *Rocz. Panstw. Zakl. Hig.*, 2016, **67**, 253–262.
- 81 V. Vichai and K. Kirtikara, *Nat. Protoc.*, 2006, **1**, 1112–1116.
- 82 A. Tiptiri-Kourpeti, E. Fitsiou, K. Spyridopoulou, S. Vasileiadis, C. Iliopoulos, A. Galanis, S. Vekiari, A. Pappa and K. Chlichlia, *Antioxidants*, 2019, **8**, 377.
- 83 K. Spyridopoulou, E. Fitsiou, E. Bouloukosta, A. Tiptiri-Kourpeti, M. Vamvakias, A. Oreopoulou, E. Papavassilopoulou, A. Pappa and K. Chlichlia, *Molecules*, 2019, **24**, 2612.
- 84 K. Spyridopoulou, A. Tiptiri-Kourpeti, E. Lampri, E. Fitsiou, S. Vasileiadis, M. Vamvakias, H. Bardouki, A. Goussia, V. Malamou-Mitsi, M. I. Panayiotidis, A. Galanis, A. Pappa and K. Chlichlia, *Sci. Rep.*, 2017, **7**, 3782.

